FIERCE-HN: A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of ficlatuzumab (HGF/cMET MAb) in combination with cetuximab in participants with recurrent or metastatic (R/M) HPV negative head and neck squamous cell carcinoma (HNSCC).

Authors: Julie E. Bauman, Lisa F. Licitra, Bhumsuk Keam, Jessica R. Bauman, Victor T. G. Lin, Neal Akhave, Jérôme Fayette, Prakash C. Neupane, Hussein Soudy, Byoung Chul Cho, Christine H. Chung, Nabil F. Saba, Deborah J.L. Wong, Kevin Joseph Harrington, Christophe Le Tourneau, Suzy Muggeo, Bo Jin, Claudia Lebedinsky, Edgar E. Braendle, Robert I. Haddad

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps6115

Source: Full article

---

Abstract

TPS6115